Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$20.56 +1.1%	$21.34	$19.00 ▼ $26.58	$2.49B	0.7	1.44 million shs	819,869 shs
GMTX Gemini Therapeutics	$58.72 +0.9%	$56.59	$1.16 ▼ $14.10	$2.54B	-0.12	189,291 shs	255,002 shs
RXRX Recursion Pharmaceuticals	$4.78 +0.2%	$5.46	$3.79 ▼ $12.36	$2.07B	0.93	20.34 million shs	14.51 million shs
TBPH Theravance Biopharma	$13.66 +2.0%	$11.42	$7.88 ▼ $14.30	$674.34M	0.01	369,254 shs	488,645 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	+1.08%	+2.44%	-1.63%	-16.05%	+0.44%
GMTX Gemini Therapeutics	+0.93%	-3.90%	-1.11%	+22.23%	+17.56%
RXRX Recursion Pharmaceuticals	+0.21%	-15.25%	-26.91%	+17.16%	-37.27%
TBPH Theravance Biopharma	+2.02%	+5.56%	+21.64%	+46.88%	+69.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPRX Catalyst Pharmaceuticals	4.9042 of 5 stars	3.6	1.0	0.0	3.9	4.0	3.3	3.8
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	2.5779 of 5 stars	3.2	1.0	0.0	0.0	3.8	2.5	0.6
TBPH Theravance Biopharma	2.1609 of 5 stars	3.8	0.0	0.0	0.0	1.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPRX Catalyst Pharmaceuticals	3.13	Buy	$33.20	61.48% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	46.44% Upside
TBPH Theravance Biopharma	3.50	Strong Buy	$21.33	56.17% Upside

Current Analyst Ratings Breakdown

Latest TBPH, GMTX, RXRX, and CPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	CPRX Catalyst Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/15/2025	TBPH Theravance Biopharma	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/8/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
7/3/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
6/27/2025	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$24.00 ➝ $25.00
6/17/2025	TBPH Theravance Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$24.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
6/5/2025	CPRX Catalyst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPRX Catalyst Pharmaceuticals	$491.73M	5.12	$2.47 per share	8.31	$6.99 per share	2.94
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
RXRX Recursion Pharmaceuticals	$58.84M	35.27	N/A	N/A	$2.12 per share	2.25
TBPH Theravance Biopharma	$64.38M	10.69	N/A	N/A	$4.46 per share	3.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPRX Catalyst Pharmaceuticals	$163.89M	$1.65	12.46	9.65	0.83	37.36%	40.78%	35.36%	11/5/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.78	N/A	N/A	N/A	-1,004.91%	-76.09%	-54.29%	11/5/2025 (Estimated)
TBPH Theravance Biopharma	-$56.42M	$0.24	56.92	39.03	N/A	16.88%	6.93%	3.52%	N/A

Latest TBPH, GMTX, RXRX, and CPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/5/2025	Q2 2025	RXRX Recursion Pharmaceuticals	-$0.35	-$0.41	-$0.06	-$0.41	$15.38 million	$19.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPRX Catalyst Pharmaceuticals	N/A	6.71	6.55
GMTX Gemini Therapeutics	N/A	71.49	71.49
RXRX Recursion Pharmaceuticals	0.02	3.58	3.58
TBPH Theravance Biopharma	N/A	6.70	6.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPRX Catalyst Pharmaceuticals	79.22%
GMTX Gemini Therapeutics	75.42%
RXRX Recursion Pharmaceuticals	89.06%
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
CPRX Catalyst Pharmaceuticals	10.40%
GMTX Gemini Therapeutics	12.90%
RXRX Recursion Pharmaceuticals	8.43%
TBPH Theravance Biopharma	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPRX Catalyst Pharmaceuticals	80	122.39 million	109.66 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
RXRX Recursion Pharmaceuticals	400	434.15 million	397.55 million	Optionable
TBPH Theravance Biopharma	110	50.36 million	46.89 million	Optionable

TBPH, GMTX, RXRX, and CPRX Headlines

Recent News About These Companies

Theravance Biopharma Settles Patent Dispute with Cipla

August 20 at 7:34 PM | msn.com

Theravance Biopharma (NASDAQ:TBPH) Hits New 1-Year High - Here's What Happened

August 20 at 11:47 AM | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Upgraded at Wall Street Zen

August 19 at 2:25 AM | americanbankingnews.com

Theravance Biopharma (NASDAQ:TBPH) Rating Increased to Strong-Buy at Wall Street Zen

August 17, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Stock Price Up 3.4% - Here's Why

August 16, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Sets New 1-Year High on Earnings Beat

August 14, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results

August 14, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Sets New 1-Year High on Strong Earnings

August 14, 2025 | americanbankingnews.com

Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

August 13, 2025 | zacks.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript

August 13, 2025 | msn.com

Theravance Biopharma Inc (TBPH) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 13, 2025 | finance.yahoo.com

Theravance Biopharma reports Q2 EPS $1.08 with items, consensus (12c)

August 12, 2025 | msn.com

Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates

August 12, 2025 | zacks.com

Theravance Bio: Q2 Earnings Snapshot

August 12, 2025 | timesunion.comT

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025 | prnewswire.com

Theravance Biopharma Q2 2025 Earnings Preview

August 11, 2025 | msn.com

Theravance Biopharma (TBPH) to Release Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

Theravance Biopharma (TBPH) to Release Earnings on Monday

July 28, 2025 | marketbeat.com

Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025

July 28, 2025 | prnewswire.com

Theravance Biopharma to Participate in an Upcoming Investor Conference

July 23, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH, GMTX, RXRX, and CPRX Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

$20.56 +0.22 (+1.08%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$20.44 -0.12 (-0.58%)

As of 08/21/2025 07:58 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Gemini Therapeutics NASDAQ:GMTX

$58.72 +0.54 (+0.93%)

As of 08/20/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Recursion Pharmaceuticals NASDAQ:RXRX

$4.78 +0.01 (+0.21%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$4.78 +0.00 (+0.10%)

As of 08/21/2025 07:59 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Theravance Biopharma NASDAQ:TBPH

$13.66 +0.27 (+2.02%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$13.66 0.00 (0.00%)

As of 08/21/2025 06:25 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time